SK pharmteco Partners with Rznomics for Gene Therapy Development

• SK pharmteco and Rznomics have signed an MOU for a multi-year partnership to develop and commercialize RNA-based gene therapies.

• The collaboration aims to transition Rznomics’ gene therapy products from clinical stages to full-scale commercial manufacturing.

SK pharmteco, a global contract development, manufacturing, and analytical testing organization, has signed a memorandum of understanding (MOU) with South Korea-based biopharmaceutical company Rznomics Inc. The agreement establishes a multi-year strategic partnership focused on developing and commercializing RNA-based gene therapies.

This collaboration will see SK pharmteco providing technical expertise and resources, including facilities and personnel, to support the transition of Rznomics’ ribonucleic acid (RNA)-based biopharmaceuticals from clinical development to full-scale commercial manufacturing. This partnership aims to facilitate the development of multiple gene therapy products.

Andy Fenny, CFO of SK pharmteco, expressed enthusiasm about the partnership, stating, “We are thrilled about the opportunity to partner with Rznomics on their groundbreaking initiatives. By combining our significant expertise in gene therapy manufacturing with Rznomics’ innovative RNA-based therapeutic approach, we believe this collaboration has the potential to deliver life-changing treatments to patients in need quickly.”

Seong-Wook Lee, President and CEO of Rznomics, highlighted the strategic importance of the partnership, noting, “This partnership will mark late-stage development and manufacturing of our gene therapy pipeline to prepare the path towards Phase II and later stage clinical trials and potential commercialization. We look forward to working closely with SK pharmteco.”